Antibiotic resistance in Escherichia coli from Nigerian students, 1986 1998. by Okeke, I. N. et al.
Dispatches
393 Vol. 6, No. 4, July–August 2000 Emerging Infectious Diseases
Resistance to antibiotics is highly prevalent
in bacterial isolates worldwide, particularly in
developing countries (1-4). Routine monitoring of
antibiotic resistance provides data for antibiotic
therapy and resistance control (5). Normal
intestinal flora are a reservoir for resistance
genes; the prevalence of resistance in commensal
Escherichia coli is a useful indicator of antibiotic
resistance in bacteria in the community (6,7).
Studies with E. coli are of particular relevance
because this species can occupy multiple niches,
including human and animal hosts (8). In
addition,  E. coli strains efficiently exchange
genetic material with pathogens such as
Salmonella, Shigella, Yersinia, and Vibrio
species, as well as pathogenic E. coli (8,9).
Few studies have evaluated antimicrobial
resistance in sub-Saharan Africa. Most available
data are specific to pathogenic organisms, and
trends over time in this region are rarely
followed. We monitored trends in antibiotic
resistance prevalence in E. coli isolates from
apparently healthy Nigerian students by mea-
suring resistance to seven antimicrobial drugs in
E. coli isolated from 758 stool specimens collected
over a 13-year period.
The Study
Stool specimens were collected from appar-
ently healthy student volunteers at the Obafemi
Awolowo University in 1986, 1988, 1994, 1996,
and 1998. The students, who provided informed
consent, were 16 to 32 years of age; 347 (45.8%)
were female. All volunteers who had taken
antimicrobial drugs or been ill in the previous
month were excluded from participation.
The specimens were collected into Stuart’s
transport medium and subcultured onto
MacConkey agar plates. Colonies with morpho-
logic characteristics of E. coli were subcultured
onto fresh plates. Identity was confirmed by
conventional biochemical tests. The standard
disk diffusion method was used for susceptibility
testing (10). The antibiotic disks used were
ampicillin (10 µg), chloramphenicol (30 µg),
streptomycin (30 µg), sulfisomidine (250 µg),
nalidixic acid (30 µg), trimethoprim (5 µg), and
tetracycline (30 µg) (AB Biodisk, Sweden). E. coli
NCTC 10418 and K-12 C600 were used as
controls. All isolates recovered at the same time
from the same person with identical biochemical
and antibiotic susceptibility profiles were
considered identical. The prevalence of resis-
tance to each drug for each year was computed.
Trends were analyzed by Pearson’s regression
and the chi-square test for trend (Mantel-
Haenszel test).
No sampling was conducted in 1990 or 1992,
and streptomycin resistance was not tested in
1994. Despite these gaps in the study, trends
toward increasing resistance in E. coli were
observed with tetracycline, sulfonamides,
ampicillin, chloramphenicol, and streptomycin
(Figure). The proportion of isolates resistant to
chloramphenicol increased from 13.5% in 1986 to
59.8% in 1998, while isolates resistant to
tetracycline increased from 34.9% to 100%. The
trends for tetracycline and streptomycin were
statistically significant (p <0.05, Pearson’s
Antibiotic Resistance in Escherichia coli
from Nigerian Students, 1986–1998
Iruka N. Okeke, Susan T. Fayinka, and Adebayo Lamikanra
Obafemi Awolowo University, Ile-Ife, Nigeria
We tested 758 fecal Escherichia coli isolates, recovered from Nigerian students in
1986, 1988, 1990, 1994, and 1998, for susceptibility to seven antimicrobial drugs. The
prevalences of strains resistant to tetracycline, ampicillin, chloramphenicol, and
streptomycin were 9% to 35% in 1986 and 56% to 100% in 1998. These findings
demonstrate that resistance gene reservoirs are increasing in healthy persons.
Address for correspondence: A. Lamikanra, Department of
Pharmaceutics, Faculty of Pharmacy, Obafemi Awolowo
University, Ile-Ife, Nigeria; fax: 234-36-231-733; e-mail:
alamikan@oauife.edu.ng.Dispatches
Emerging Infectious Diseases Vol. 6, No. 4, July–August 2000 394
Figure. Percentage of isolates resistant to seven
antimicrobial drugs, 1986-1998.
*No data are available for streptomycin in 1994.
Table. Proportions of universally susceptible and
multiply resistant Escherchia coli, Nigeria, 1986–1998
No. (%) isolates
Sensitive
Yr/(No. to all Resistant Resistant
isolates) drugs tested to 3 drugs to 6 drugs
1986/(63) 19 (30.2)   19 (30.2)   1 (1.6)
1994/(222)a 24 (15.4)   37 (23.7)   0 (0)
1996/(185) 34 (18.4) 105 (56.8)   6 (3.2)
1998/(132)   0 (0)   93 (70.5) 21 (15.9)
p valueb -0.768 (0.232) 0.960 (0.04) 0.768 (0.232)
aStreptomycin was not tested in 1994.
bp value based on Pearson’s regression coefficient for
trend.
regression; p <0.10, chi-square test for trend).
The prevalence of sulfonamide resistance
increased sharply from 1986 to 1988 (from 25.4%
to 74.3%), then remained fairly constant. The
moderate levels of resistance to trimethoprim
(35.7% and 47.6%) and low levels to nalidixic acid
(0% to 3.2%) did not change appreciably.
As strains susceptible to all drugs became
less common, the proportion of isolates resistant
to multiple antibiotics increased (Table). In 1986,
19 (30.2%) isolates were susceptible to all the
drugs tested, but by 1998 all the isolates were
resistant to at least one drug. The proportion of
isolates resistant to three or more drugs
increased steadily, from 30.2% in 1986 to 70.5%
in 1998 (p <0.05, Pearson’s regression; p <0.10,
chi-square test for trend). Only one isolate from
1986 was resistant to at least six drugs, but 15.9%
of the isolates obtained in 1998 demonstrated
this phenotype. Three isolates were resistant to
all drugs tested. Two of these had only low levels
of resistance to nalidixic acid and chlorampheni-
col (in both cases) and ampicillin in one case. One
isolate recovered in 1998 had high-level resistance
to all the drugs tested, as well as to cefalotin and
fluoroquinolones (ofloxacin, ciprofloxacin, and
norfloxacin); however, it was susceptible to
spectinomycin, tobramycin, and gentamicin.
Conclusions
Residents in and visitors to developing
countries acquire antibiotic-resistant E. coli as
part of their normal flora (1,2,11). Our data show
that the prevalence of resistance to most drugs
tested in E. coli isolates from apparently healthy
students is within the high range reported
previously (2) and has increased from 1986 to
1998. The increases in prevalence of resistance to
streptomycin and tetracycline were statistically
significant. In most drugs tested, the proportion
of resistance isolates has increased rapidly, so
that the usefulness of drugs moderately effective
in 1986 has been severely compromised. The
prevalence of resistance in these commensal
E. coli during the latter sampling points
reached  >50% in 1998 for all drugs except
trimethoprim and nalidixic acid. For tetracy-
cline, the proportion of resistant strains
increased from <40% to 100% in the 13-year
period. As in other studies (2), the general trend
toward increasing prevalence of resistance was
marked by the recovery of an increasing
proportion of strains that were simultaneously
resistant to several drugs. These data sound a
warning because the indiscriminate use of
antibiotics, along with poor hygiene and infection
control (risk factors for antibiotic resistance in
bacteria) are highly prevalent in Nigeria and
other developing countries (4,12).
The five drugs for which a considerable rise in
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(ampicillin, sulfonamides, streptomycin, chloram-
phenicol, and tetracycline) are extensively used
in Nigeria and other developing countries (4,12).
These five inexpensive drugs are widely available
without prescription from authorized health
institutions and pharmacies, as well as from
unauthorized patent medicine shops and other
distributors (4,12). Streptomycin, which must be
injected, and chloramphenicol, because of its
toxicity, are less popular than the other three
drugs—and had lower resistance prevalence—
but are nonetheless used more often than
indicated. The prevalence of resistance to a sixth
agent, nalidixic acid, remained low, correspond-
ing to the low consumption of this and related
drugs in health institutions and the community.
The recent introduction of fluoroquinolones in
clinical practice may alter this profile, since
resistance to the fluoroquinolones and nalidixic
acid has been shown to spread rapidly (3,13).
Resistance to trimethoprim was higher than
to other drugs in 1986 but did not increase
substantially in subsequent years. This drug is
heavily used in health institutions and in the
community, generally in combination with
sulfamethoxazole. The selective pressure gener-
ated by overuse explains the relatively high
prevalence of resistance in E. coli isolates in
1986. However, it is not clear why the trend
observed with other widely used drugs was not
seen in this case. Any increases in prevalence of
strains resistant to trimethoprim may have
occurred before 1986. A similar plateau with
sulfonamide resistance followed a rapid rise from
1986 to 1988. Why this plateau was seen with
two drugs and not others is not known, but the
observation has been reported in other
locations (14).
Ingestion of antibiotics is known to provide
selective pressure ultimately leading to a higher
prevalence of resistant bacteria, even among
persons who have not taken antibiotics (7,8). As
recent antibiotic use was a criterion for exclusion
from the study, selection of the resistance strains
isolated in the study may have occurred before
the volunteer hosts were colonized. The source of
resistant organisms in our study population is
not known, but possible sources are food, water,
and person-to-person transfer. Suboptimal sani-
tary conditions and overcrowding in student
hostels may facilitate the spread of these
organisms.
We observed rapid increases in the preva-
lence of resistance in commensal E. coli to most of
the older, less expensive antimicrobial drugs
used in the management of infections in Nigeria.
Not only are these strains potential causes of
infection, but they are also potential reservoirs of
resistance genes that could be transferred to
pathogens. For this reason, the trends seen with
commensal  E. coli may also occur with
pathogenic organisms. Studies in other develop-
ing countries have shown that the trend in
enteric pathogens is toward increasing antibiotic
resistance (3). Our study emphasizes the need to
monitor commensal organisms as well as
pathogens by susceptibility testing to guide
treatment. Control of antibiotic resistance is
needed to conserve the usefulness of the
remaining drugs. The data suggest that nalidixic
acid and possibly trimethoprim may be useful in
treating infections caused by pathogenic E. coli
and other related bacteria in Nigeria. The future
usefulness of these drugs will, however, depend
on effective interventions to halt the selection
and spread of resistance among enteric organisms.
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